BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10914933)

  • 1. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of radioactive phosphorus in haematology.
    Roberts BE; Smith AH
    Blood Rev; 1997 Sep; 11(3):146-53. PubMed ID: 9370045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
    Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR
    N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EANM procedure guidelines for 32P therapy.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP17-9. PubMed ID: 12723560
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S; Rosenthal DS; Weinfeld A; Briere J; Faguet GB; Knospe WH; Landaw SA; Laszlo J; Pisciotta AV; Tartaglia AP
    Cancer Treat Rep; 1982 Jul; 66(7):1495-500. PubMed ID: 7046930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential thrombocythemia following polycythemia vera: an unusual sequence.
    Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
    J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
    Najean Y; Rain JD
    Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera: a retrospective and reprise.
    Berlin NI; Wasserman LR
    J Lab Clin Med; 1997 Oct; 130(4):365-73. PubMed ID: 9358074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative diseases.
    Silverstein MN
    Postgrad Med; 1977 Feb; 61(2):206-10. PubMed ID: 556856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.
    Najean Y; Dresch C; Rain JD
    Nouv Rev Fr Hematol (1978); 1978 Nov; 20(3):377-85. PubMed ID: 112580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.